Asia Pacific Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Botulinum toxin A and Botulinum toxin B), Application (Medical and Aesthetic), and End User (Speciality and Dermatology Clinics, Hospitals and Cl

Asia Pacific Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Botulinum toxin A and Botulinum toxin B), Application (Medical and Aesthetic), and End User (Speciality and Dermatology Clinics, Hospitals and Clinics, and Others)

The Asia Pacific botulinum toxin market is expected to reach US$ 1,019.0 million by 2028 from US$ 645.4 million in 2021. The market is estimated to surge at a CAGR of 6.7% from 2021 to 2028.

BTX is mainly used in neurorehabilitation to treat spasticity and prevent muscle contractures. It has revolutionized the treatment of various spastic eye disorders, facial dystonia, and periocular folds. The precise knowledge and understanding of the functional anatomy of the facial muscles are necessary to ensure the appropriate use of BTX in clinical practice. In the near future, the development of new potent toxins for increasing potency and duration of action is likely to offer lucrative opportunities for market expansion in Asia Pacific.

With these new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the botulinum toxin market at a significant CAGR during the forecast period.

Asia Pacific Botulinum Toxin Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Botulinum Toxin Market Segmentation

By Product Type

Type A Botulinum Toxin Type B Botulinum Toxin By Application

Medical Chronic Migraine Muscle Spasm Over Reactive Bladder Hyperhidrosis Others Aesthetic Crow’s Feet Forehead Lines Frown Lines/ Glabellar Square Jaw/ Masseter Others

By End-User

Specialty And Dermatology Clinics Hospitals And Clinics Others

By Country

Asia Pacific China Japan India South Korea Australia Rest of Asia Pacific

Companies Mentioned

Abb Vie Inc. Merz Pharma Medytox Sanofi Ipsen Pharma Galderma Lanzhou Institute of Biological Products Co., Ltd. Candela Medical Daewoong Pharmaceutical Co. Ltd.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific botulinum toxin market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific botulinum toxin market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.